Registry Data Show RED Reperfusion Catheters are Effective for Stroke Care

Penumbra Inc. is touting initial INSIGHT Registry data that shows its RED reperfusion catheters were successful in removing all clot types. Additionally, results of sub-analyses of the COMPLETE study showed use of the Penumbra System is effective for acute ischemic stroke (AIS) patients with tandem lesions, as well as patients who are considered in the late window of treatment. 
 
“The initial data from our INSIGHT Registry is very promising. With such a high first pass rate, Penumbra’s RED catheters can restore blood flow much quicker, which we know can lead to improved outcomes for patients,” said Sandra Lesenfants, president of interventional at Penumbra Inc. “Penumbra’s focus has always been to help as many people as we can, and this data demonstrates that our latest technology is indeed making a positive impact.”
 
The initial INSIGHT Registry data evaluating Penumbra’s latest RED reperfusion catheters in 161 AIS patients showed 68.9% had successful first-pass revascularization (mTICI≥2b-3), and 97% had successful revascularization after final angiogram through site reported findings. Final mTICI≥2b-3 scores were reported in 98.1% of patients with firm-red clots and in 100% of patients with other clot types. The INSIGHT Registry is a multicenter post-market evaluation.
 
“Mechanical aspiration thrombectomy is becoming an increasingly important option for physicians treating acute ischemic stroke, especially patients with more complicated cases,” said Osama Zaidat, M.D., the national principal investigator of the COMPLETE study. “Oftentimes, patients that presented late or have tandem lesions (15% of MT cases) are difficult to treat. However, the data showed the Penumbra System delivered good functional outcomes and low 90-day mortality rates for these patients, which compared favorably to other options.”
 
COMPLETE is a global, prospective, multicenter post-market study assessing the performance of the company’s Penumbra System. The Core Lab adjudicated findings include:

• Patients with anterior circulation tandem lesions with stenosis greater than 50% treated with Penumbra System resulted in successful revascularization: 89% of patients achieved mTICI 2b-3 and nearly 64% of patients achieved 90-day mRS 0-2.
• Late window patients achieved successful revascularization with the use of the Penumbra System in 83.2% of cases, with a 90-day good functional outcome rate of 55.4%. Additionally, there were no device related adverse events observed.

 
“The presented data confirms that Penumbra’s aspiration thrombectomy innovations are highly effective. Our drive to advance novel technologies allows us to provide physicians with the broadest portfolio of proven solutions for stroke management,” continued Lesenfants.
 
Penumbra Inc., headquartered in Alameda, Calif., is a global healthcare company that designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries.